Clinical detection of oncogenic point mutations conferring enzymatic gain-of-function has been a fruitful strategy for triaging patients to molecularly targeted therapy in several cancer types, including lung adenocarcinoma (EGFR mutations) [19] and melanoma (BRAF V600E mutations). Here, BRAF is linked to lung adenocarcinoma.